Physician

Mark Andrew Walshauser, M.D.

According to 2025 Medicare claims, Mark Walshauser, M.D. (NPI: 1306020664) practices hematology/oncology in the St. Louis, MO-IL market, with the plurality of this provider's patient population coming from St. Clair, IL. This provider's primary affiliated billing organization is CANCER CARE SPECIALISTS OF CENTRAL ILLINOIS, S.C. (NPI: 1871580142; TIN: 371160364) and primary practice location at 62269-1887. Walshauser is affiliated with the IRCCO (ACO ID: A2619) and IHCI ACO Midwest LLC (ACO ID: A5516), participating under the MSSP model.

Walshauser's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 524 traditional Medicare patients, billed 211,909 HCPCS/CPT codes, and received $3,162,406 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,534 prescription claims across 283 beneficiaries totaling $3,936,064 in drug costs, led by Ibrance (Palbociclib). DME data shows 58 claims. Open Payments data shows 93 records totaling $9,265. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $293,680 to $3,162,406. Similarly, Part D prescription costs have risen steadily, from $65,464 to $3,936,064. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	179	38,094	$293,680
2016	296	94,258	$643,978
2017	484	174,442	$1,655,205
2018	506	205,707	$2,409,191
2019	512	184,797	$1,981,088
2020	536	204,504	$2,271,299
2021	574	243,770	$3,729,332
2022	522	209,507	$3,209,916
2023	487	215,874	$2,907,651
2024	524	211,909	$3,162,406

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	49	311	$65,464
2016	99	678	$506,808
2017	158	1,130	$1,548,204
2018	197	1,619	$2,594,635
2019	193	1,506	$3,389,173
2020	228	1,729	$4,095,420
2021	248	1,841	$4,783,181
2022	245	1,817	$4,995,386
2023	235	1,376	$3,561,545
2024	283	1,534	$3,936,064

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	50	$1,372
2016	N/R	N/R	N/R
2017	N/R	69	$19,047
2018	N/R	92	$15,461
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	52	$7,789
2024	N/R	58	$837

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	307	988	$92
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	338	699	$13
80053	Blood test, comprehensive group of blood chemicals	291	1,022	$10
36415	Insertion of needle into vein for collection of blood sample	311	907	$9
83615	Lactate dehydrogenase (enzyme) level	217	720	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	50	1,400	$751,859
Pomalyst	Pomalidomide	33	924	$734,103
Revlimid	Lenalidomide	21	553	$438,842
Lenalidomide	Lenalidomide	20	560	$392,858
Cabometyx	Cabozantinib S-Malate	12	360	$271,039

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8530	Cyclophosphamide; oral, 25 mg	N	N/R	30	$486
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	28	$351

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	93	$9,265	Regeneron Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark Andrew Walshauser, M.D.?

Tedicare shows public-source Medicare data for Mark Andrew Walshauser, M.D. (NPI 1306020664), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Andrew Walshauser, M.D. have ACO affiliation data?

Mark Andrew Walshauser, M.D. is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619) and IHCI ACO Midwest LLC (MSSP, ACO ID A5516).

What billing organization is linked to Mark Andrew Walshauser, M.D.?

Mark Andrew Walshauser, M.D. is linked to CANCER CARE SPECIALISTS OF CENTRAL ILLINOIS, S.C. (billing NPI 1871580142) in the available physician profile data.

Does Mark Andrew Walshauser, M.D. have Open Payments data?

Mark Andrew Walshauser, M.D. has 93 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.